When a cervical cytology report carries the phrase 'reactive cellular change', it is easy to worry first about whether it means cancer. To give the conclusion first, it is a normal response of the cells to inflammation or irritation, and it is not a disease that needs treatment. This article explains where reactive cellular change sits among the possible results, and when regular screening and an HPV test are needed.
Anxiety often grows when people try to interpret the report on their own, but knowing what each stage means makes it easier to judge when another consultation is needed.
What kind of condition is reactive cellular change?
A cervical cytology test grades the degree of abnormality in order: stage 1 reactive cellular change, stage 2 atypical squamous cells, stage 3 squamous intraepithelial lesion and stage 4 cervical cancer. Reactive cellular change can appear from inflammation alone, regardless of any viral infection, so it is classed in a fundamentally different category from cancer and is not a target for treatment.
In data that followed 45 cases, 87.9% of those reported as reactive cellular change had improved at the retest without any particular treatment, and only the remaining 10.2% went on to a finding that needed further observation. This shows that most reactive cellular change is no more than a temporary change, but anyone who receives this result should still keep to the recommended time for the retest.
- Stage 1 reactive cellular change — a normal response to inflammation or irritation, a benign finding unrelated to cancer
- Stage 2 atypical squamous cells — the shape of the cells is irregular, so further confirmation such as an HPV test is needed
- Stage 3 squamous intraepithelial lesion — actual precancerous cell change is observed, so detailed diagnosis is recommended
- Stage 4 cervical cancer — the stage at which an invasive lesion is confirmed, and a treatment plan is needed immediately

When should the next test be, and what should you do until then?
At the stage of early cell change there are almost no symptoms a person can notice, such as bleeding or pain, and the related viral infection also takes hold in the cervical cells without discomfort. As a result, by the time someone senses that something is wrong and visits a clinic, the change has in many cases already progressed considerably.
Looking at the time taken to reach a confirmed diagnosis, cases found early through regular screening took an average of 2.92 months, whereas cases confirmed at the stage of advanced cancer after symptoms had appeared took an average of 10.5 months, so the time to diagnosis differed widely depending on when screening took place.

How are the HPV test and the retest interval decided from the cytology result?
The cervical cytology test identifies changes in the shape of the cells, while the HPV test confirms whether the related virus is present, so the two examine different points. If the cytology result is reactive cellular change with no other abnormality, there is little need to add an HPV test straight away at this stage.
If both the cytology test and the HPV test are normal, a retest on a 2 year cycle is recommended; if the HPV test is positive or an earlier result showed an abnormal finding, the recommended cycle is 1 year. Screening generally begins from the age of 20 even without particular symptoms, and it is safer not to lengthen the interval on your own because a result once came back normal.
- Atypical squamous cells or above — an HPV test is carried out alongside to confirm whether infection is present
- Repeated reactive cellular change — if the same finding continues at the retest, an HPV test is considered
- Cytology test and HPV test both normal — regular screening on a 2 year cycle is sufficient
